Lilly beefs up bowel disease drug portfolio with $3.2 bln Morphic deal
Updates share movement in paragraph 2
By Sriparna Roy
July 8 (Reuters) -Eli Lilly LLY.N agreed to buy Morphic Holding MORF.O for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of inflammatory bowel disease (IBD) drugs and expanding its footprint in the multi-billion dollar market.
Shares of Waltham, Massachusetts-based Morphic surged nearly 75% to $55.62 in morning trading on Lilly's offer of $57 per share, which represents a 79% premium to the stock's last closing price.
Through the deal, Lilly will procure an experimental oral IBD treatment that offers patients a more convenient dosing option compared to other injectable therapies, including its IBD drug Omvoh that was approved last year.
Along with Lilly, other drugmakers such as Abbvie Inc ABBV.N, Pfizer PFE.N and Johnson & Johnson JNJ.N are also jostling for a share of the bowel disease market.
IBD collectively refers to two conditions - Crohn's disease and ulcerative colitis- that are characterized by chronic inflammation of the gastrointestinal tract and are caused by abnormal reactions of the immune system.
Lilly counts its IBD drug, Omvoh, among its future growth drivers, besides its blockbuster weight loss treatment Zepbound and diabetes drug Mounjaro.
Morphic's lead drug MORF-057 is being tested in three mid-stage studies to treat two bowel conditions called ulcerative colitis and Crohn's disease.
Morphic is also developing other drugs, which are being tested in animals or test tube experiments, for autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer.
The companies expect the acquisition to close in the third quarter of 2024.
The deal fits into Lilly's plans to diversify beyond obesity and adds to its string of recent "bolt-on" deals, said BMO analyst Evan Seigerman, referring to acquisitions below the $10 billion range.
The Morphic deal comes after a spate of acquisitions by Lilly last year such as its $2.4 billion buyout of Dice Therapeutics and $1.4 billion agreement for Point Biopharma Global PNT.O.
Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
